8-KOther Events

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Nov 16, 2010)

Filed November 16, 2010For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on November 16, 2010, that it has exercised its right to terminate the single-stranded RNAi (ssRNAi) collaborative effort and associated licenses with Isis Pharmaceuticals, Inc. This termination is effective as of November 12, 2010. The termination ends Alnylam's obligation to make further research funding payments, including a $10.0 million license fee due in the fourth quarter of 2010, as well as any future milestone payments, royalties, or sublicense payments to Isis related to ssRNAi products. This decision effectively concludes Alnylam's involvement in the ssRNAi research program with Isis. Importantly, the termination does not impact the broader collaboration concerning double-stranded RNAi (dsRNAi) technology, for which Alnylam retains its licenses. Investors should note this strategic shift away from ssRNAi development with Isis, while recognizing the continued collaboration on dsRNAi, which remains a core focus for Alnylam.

Key Highlights

  • 1Alnylam Pharmaceuticals terminated its ssRNAi collaborative effort and associated licenses with Isis Pharmaceuticals, effective November 12, 2010.
  • 2The termination releases Alnylam from future research funding obligations, including a $10.0 million license fee due in Q4 2010.
  • 3All milestone payments, royalties, and sublicense payments related to ssRNAi products to Isis are also terminated.
  • 4This action allows Alnylam to cease financial commitments specifically tied to the ssRNAi program.
  • 5The termination does not affect Alnylam's existing licenses and collaboration with Isis for double-stranded RNAi (dsRNAi) technology.
  • 6The broader cross-licensing arrangement for dsRNAi, established in 2004 and amended in 2009, remains in full force.

Frequently Asked Questions

The primary event is Alnylam Pharmaceuticals exercising its unilateral right to terminate the single-stranded RNAi (ssRNAi) collaborative research effort and all related licenses with Isis Pharmaceuticals, effective November 12, 2010.

The termination releases Alnylam from its obligation to fund further research activities and pay a $10.0 million license fee due in the fourth quarter of 2010. It also eliminates any future milestone payments, royalties, or sublicense payments to Isis related to ssRNAi products.

No, the termination specifically pertains to the ssRNAi collaborative effort. Alnylam's licenses and the collaboration with Isis concerning double-stranded RNAi (dsRNAi) technology remain unaffected and will continue in full force and effect.

The filing states that Alnylam had a unilateral right to terminate the ssRNAi research program. While the specific reasons for exercising this right are not detailed, it implies a strategic decision by Alnylam to discontinue its focus on ssRNAi development under this particular agreement, likely due to strategic priorities or assessment of the program's future.